Showing results (1201-1210 of 2,357) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|January 1, 1984
In vitro binding of amantadine to plasma proteinsP Liu, P J Cheng, T S Ing, et al.Clinical Neuropharmacology|January 1, 1984
Assessment of Parkinson's diseaseT A Larsen, S Calne, D B CalneClinical Neuropharmacology|January 1, 1993
Reversible monoamine oxidase-A inhibitors in resistant major depressionW A Nolen, E Hoencamp, P F Bouvy, et al.Clinical Neuropharmacology|February 1, 1995
Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's diseaseE Mohr, V Knott, M Sampson, et al.Clinical Neuropharmacology|February 1, 1995
Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosisA E Lang, P Sandor, J DuffClinical Neuropharmacology|February 1, 1995
Valproic acid in ultra-rapid cycling: a case reportE Lepkifker, I Iancu, P Dannon, et al.Clinical Neuropharmacology|August 1, 1995
Possible therapeutic application of GABAB receptor agonists and antagonistsM Malcangio, N G BoweryClinical Neuropharmacology|August 1, 1995
Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitorsD Aizenberg, Z Zemishlany, A WeizmanClinical Neuropharmacology|August 1, 1995
A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's diseaseT Corona, C Rivera, E Otero, et al.Clinical Neuropharmacology|August 1, 1995
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegilineT L Davis, M Roznoski, R S BurnsPageof 236